---
title: "Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283857416.md"
description: "Livzon Pharmaceutical Group has scheduled its 2025 annual general meeting for May 29, 2026, in Zhuhai, allowing both on-site and online voting. The agenda includes approval of the annual report, reappointment of Grant Thornton as auditor, and a cash dividend plan of RMB14.3 per 10 shares. The company emphasizes its commitment to returning cash to investors. The latest analyst rating for Livzon Pharmaceutical (HK:1513) is a Sell, with a price target of HK$22.99."
datetime: "2026-04-23T14:41:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283857416.md)
  - [en](https://longbridge.com/en/news/283857416.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283857416.md)
---

# Livzon Pharmaceutical Sets 2025 AGM to Approve Results and Cash Dividend Plan

### Claim 30% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Livzon Pharmaceutical Group ( (HK:1513) ) has issued an announcement.

Livzon Pharmaceutical Group has called its 2025 annual general meeting for 29 May 2026 in Zhuhai, combining on-site and online voting for shareholders. The agenda covers approval of the 2025 annual report, board work report and financial accounts, reappointment of Grant Thornton as auditor for 2026, and a cash dividend distribution plan.

Shareholders will vote on reappointing Grant Thornton for 2026 with specified fees for financial statement and internal control audits. They will also consider a 2025 profit distribution proposal to pay a cash dividend of RMB14.3 per 10 shares, with no bonus shares or capitalisation of reserves, underscoring the company’s commitment to returning cash to investors.

The most recent analyst rating on (HK:1513) stock is a Sell with a HK$22.99 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.

**More about Livzon Pharmaceutical Group**

Livzon Pharmaceutical Group Inc. is a China-based pharmaceutical company engaged in the research, production and sale of medicines and healthcare products. Listed in Hong Kong and Shenzhen, it focuses on prescription drugs and related medical products, serving domestic and international healthcare markets.

**Average Trading Volume:** 914,703

**Technical Sentiment Signal:** Buy

**Current Market Cap:** HK$31.41B

### Related Stocks

- [01513.HK](https://longbridge.com/en/quote/01513.HK.md)
- [000513.CN](https://longbridge.com/en/quote/000513.CN.md)

## Related News & Research

- [CICC Reaffirms Their Buy Rating on Livzon Pharmaceutical Group (LVZPF)](https://longbridge.com/en/news/282769048.md)
- [The Trading Awards: Voting is open until 19 May](https://longbridge.com/en/news/286793607.md)
- [Wide postpones 2026 annual meeting to June 17; proxy voting deadline June 16](https://longbridge.com/en/news/286911986.md)
- [ARTRARI ONE CAPITAL CORP. REPORTS ON VOTING RESULTS FROM THE 2026 ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS](https://longbridge.com/en/news/286606232.md)
- [Triumph New Energy Sets 2025 AGM to Approve Profit Plan, Auditor and Board Changes](https://longbridge.com/en/news/287049811.md)